The verdict, with the defendable data behind it. Question on the table: should openfootlab.com be the condition-agnostic lab / intelligence domain that feeds the ecosystem?
"I personally see my foot health as my #1 condition — not diabetes. I understand diabetes increases complications and high risk — yes. But the foot is what I manage."
This is the entire thesis, said by the person who lives it. It is more defensible than the diabetes framing, not less: the moat was never "I live diabetes" — it's "I live the at-risk foot." Diabetes is a risk multiplier, not the condition being managed. If the founder — a type-1 diabetic post-amputation — ranks foot health above diabetes, then a foot-at-risk platform is the honest product, and a foot intelligence domain (openfootlab.com) is its honest home. The diagnosis is the setting; the foot is the subject.
Build openfootlab.com as the intelligence layer — the home of the models, the studies, the Foot Passport open spec, the datasets, the evals, and the clinical-review program. It feeds the consumer products (LocalDiabetic is the flagship, driven by the lived-diabetic moat; athletes, amputees, neuropathy patients are future front doors). It does not replace LocalDiabetic and it must consolidate the foot-lab intelligence, not add sprawl.
1. The intelligence is foot-health, and that's defendable beyond diabetes. You can only name a lab after what it actually studies. The thing we're building — capture standards, the MedGemma foot models, the observation schema, the passport spec, the LocalStudies — is foot-health intelligence. It is not diabetes-specific, and the data proves it (below). Boxing it under "OpenDiabetic" mislabels the asset and structurally caps who can draw on it.
2. A neutral hub is the only thing every segment can share. A diabetic can't be the front door for an athlete, an amputee, or a chemo patient with neuropathy — "opendiabetic.com" actively repels them. "openfootlab.com" invites all of them. One lab, many products.
3. Separation of concerns = leverage. Lab (intelligence) vs Product (the app someone uses). The lab cooks once and feeds many. LocalDiabetic consumes it for the diabetic wedge; a future "performance foot" product consumes the same models and passport for athletes. You build the expensive thing (models, evals, spec) once.
4. A "lab" is where you publish receipts — which is the whole ethos. LocalStudy (FL-STUDY-001), the Foot Passport open spec, the golden set, the MedGemma accuracy work, the clinician-review program — these read as research infrastructure. That's defendability made visible. A lab domain is the natural, credible home for "proven, not promised."
5. The Foot Passport is already condition-agnostic (spec v1.0, prompt v2, free-text profile). It was built to hold any at-risk foot. It wants a condition-agnostic home. openfootlab.com is it.
earns its place if it is THE singular lab hub that consolidates the foot intelligence currently split between opendiabetic.com and the passport work — not a tenth scattered site. One logo, one design, one voice (brand discipline holds).
personal, defensible edge. LocalDiabetic stays the flagship consumer product and the human story. OpenFootLab is the engine underneath, not a rebrand away from it.
datasets); consumer products link up to it as the source of truth. Avoid duplicate foot content competing between opendiabetic.com and openfootlab.com — pick the canonical home and redirect.
real hub or not at all.
Foot risk is defined by a mechanism, not a diagnosis — can't feel it (neuropathy), can't heal it (ischemia), can't take the pressure (deformity/missing tissue). None require diabetes:
leading cause) and only ~2/3 of the vascular half is diabetic → more than half of amputees are not diabetic. [Ziegler-Graham 2008; NTDB]
chemo patients (persists in ~58% of breast-cancer survivors); Charcot-Marie-Tooth (most common hereditary neuropathy); spinal cord injury (pressure-ulcer prevalence 23–39%); spina bifida; leprosy — the #1 cause of the insensate foot worldwide; rheumatoid arthritis (foot involvement 30–90%, ulcers ~10%). [PMC sources in Foot-Risk-Beyond-Diabetes.md]
runners*; black toenail, stress fractures, blisters — foot problems that end seasons. A large, self-motivated, non-medical* wedge. [NCAA data; plantar-fasciitis reviews]
4 practices per year); the owned, portable, longitudinal passport is the continuity the system can't provide.
Conclusion: "other conditions require foot-health monitoring" is not a claim — it's the epidemiology. That confirms the premise, so the answer to "then do we build the neutral lab domain?" is yes.
golden-set scores.
clinically-sound (Dr. G is the first reviewer).
Consumer products (LocalDiabetic first) draw from all of it. OpenFootLab is the brain; the apps are the hands.
Positioning line: "OpenFootLab — the foot-health intelligence that feeds the ecosystem. You don't have to be diabetic to need it."